Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy effect on chronic lymphocytic leukemia
Summary:
Analysis of CD19+ selected B cells from CLL patients before and after chemoimmunotherapy regimens of rituximab (R), fludarabine and cyclophosphamide (FC), or RFC. Results provide insight into the molecular mechanisms underlying the beneficial effects of the chemoimmunotherapy regimens.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Shehata M, Demirtas D, Schnabl S, Hilgarth M et al. Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. Leukemia 2010 Dec;24(12):2122-7. PMID: 20966934
